Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 419-433

  Gasparini, Laura ^a   Anthony Crowther, R ^b   Martin, Keith R ^a   Berg, Nicola ^a   Coleman, Michael ^c   Goedert, Michel ^b   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Alzheimer disease; Axonopathy; Frontotemporal dementia; Retinal ganglion cells; Tau; Tauopathy

Indexed keywords

TAU PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AXON ELONGATION; CONTROLLED STUDY; MOUSE; NERVE DEGENERATION; NERVE FIBER; NERVE FIBER GROWTH; NONHUMAN; OPTIC DISK; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; RETINA GANGLION CELL; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; AXONS; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; INCLUSION BODIES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MUTATION; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; OPHTHALMOSCOPY; ORGAN CULTURE TECHNIQUES; PHOSPHORYLATION; PROLINE; RETINAL GANGLION CELLS; SERINE; TAU PROTEINS; TAUOPATHIES;

EID: 79952897585     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.03.002     Document Type: Article

References (63)

1. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
2. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 2006, 580:2922-2927.
3. Bancher C., Brunner C., Lassmann H., Budka H., Jellinger K., Wiche G., Seitelberger F., Grundke-Iqbal I., Iqbal K., Wisniewski H.M. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989, 477:90-99.
4. Bates C.A., Meyer R.L. The heavy neurofilament protein is expressed in regenerating adult but not embryonic mammalian optic fibers in vitro. Exp. Neurol. 1993, 119:249-257.
5. Beirowski B., Berek L., Adalbert R., Wagner D., Grumme D.S., Addicks K., Ribchester R.R., Coleman M.P. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. J. Neurosci. Methods 2004, 134:23-35.
6. Bellucci A., Westwood A.J., Ingram E., Casamenti F., Goedert M., Spillantini M.G. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 2004, 165:1643-1652.
7. Blanks J.C., Hinton D.R., Sadun A.A., Miller C.A. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res. 1989, 501:364-372.
8. Braak E., Braak H., Mandelkow E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994, 87:554-567.
9. Buckingham B.P., Inman D.M., Lambert W., Oglesby E., Calkins D.J., Steele M.R., Vetter M.L., Marsh-Armstrong N., Horner P.J. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J. Neurosci. 2008, 28:2735-2744.
10. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J., Golland P., Sabatini D.M. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7:R100-R1100. 10.
11. Crowther R.A. Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2288-2292.
12. Dixit R., Ross J.L., Goldman Y.E., Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008, 319:1086-1089.
13. Dubey M., Chaudhury P., Kabiru H., Shea T.B. Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: neurofilaments attenuate tau-mediated neurite instability. Cell Motil. Cytoskeleton 2008, 65:89-99.
14. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
15. Ferrari A., Hoerndli F., Baechi T., Nitsch R.M., Götz J. Beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 2003, 278:40162-40168.
16. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
17. Gasparini L., Terni B., Spillantini M.G. Frontotemporal dementia with tau pathology. Neurodegenerative Dis. 2007, 4:236-253.
18. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
19. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989, 3:519-526.
20. Goedert M., Klug A., Crowther R.A. Tau protein, the paired helical filament and Alzheimer's disease. J. Alzheimer's Disease 2006, 9:195-207.
21. Goldberg J.L., Espinosa J.S., Xu Y., Davidson N., Kovacs G.T., Barres B.A. Retinal ganglion cells do not extend axons by default: promotion by neurotrophic signaling and electrical activity. Neuron 2002, 33:689-702.
22. Greeve I., Kretzschmar D., Tschape J.A., Beyn A., Brellinger C., Schweizer M., Nitsch R.M., Reifegerste R. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 2004, 24:3899-3906.
23. Guo L., Salt T.E., Luong V., Wood N., Cheung W., Maass A., Ferrari G., Russo-Marie F., Sillito A.M., Cheetham M.E., Moss S.E., Fitzke F.W., Cordeiro M.F. Targeting amyloid-beta in glaucoma treatment. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13444-13449.
24. Gupta N., Fong J., Ang L.C., Yucel Y.H. Retinal tau pathology in human glaucomas. Can. J. Ophthalmol. 2008, 43:53-60.
25. Haverkamp S., Wässle H. Immunocytochemical analysis of the mouse retina. J. Comp. Neurol. 2000, 424:1-23.
26. Iqbal K., Grundke-Iqbal I. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J. Alzheimer's Disease 2006, 9:219-242.
27. Iseri P.K., Altinas O., Tokay T., Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 2006, 26:18-24.
28. Jackson G.R., Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol. Clin. 2003, 21:709-728.
29. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
30. Karsten S.L., Sang T.K., Gehman L.T., Chatterjee S., Liu J., Lawless G.M., Sengupta S., Berry R.W., Pomakian J., Oh H.S., Schulz C., Hui K.S., Wiedau-Pazos M., Vinters H.V., Binder L.I., Geschwind D.H., Jackson G.R. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 2006, 51:549-560.
31. Khlistunova I., Biernat J., Wang Y., Pickhardt M., von Bergen M., Gazova Z., Mandelkow E., Mandelkow E.M. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 2006, 281:1205-1214.
32. Ko L.W., Rush T., Sahara N., Kersh J.S., Easson C., DeTure M., Lin W.L., Connor Y.D., Yen S.H. Assembly of filamentous tau aggregates in human neuronal cells. J. Alzheimer's Disease 2004, 6:605-622.
33. Leroy K., Bretteville A., Schindowski K., Gilissen E., Authelet M., De Decker R., Yilmaz Z., Buee L., Brion J.P. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am. J. Pathol. 2007, 171:976-992.
34. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., van Slegtenhorst M., Gwinn-Hardy K., Paul M.M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
35. Magnani, E., Raha-Chowdhury, R., Emson, P.C., Goedert, M., Spillantini, M.G., 2004. Generation of a transgenic mouse model with tau and -synuclein pathology. In: Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC, online.
36. Magnani E., Fan J., Gasparini L., Golding M., Williams M., Schiavo G., Goedert M., Amos L.A., Spillantini M.G. Interaction of tau protein with the dynactin complex. EMBO J. 2007, 26:4546-4554.
37. McKinnon S.J., Lehman D.M., Kerrigan-Baumrind L.A., Merges C.A., Pease M.E., Kerrigan D.F., Ransom N.L., Tahzib N.G., Reitsamer H.A., Levkovitch-Verbin H., Quigley H.A., Zack D.J. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2002, 43:1077-1087.
38. Meijering E., Jacob M., Sarria J.C., Steiner P., Hirling H., Unser M. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 2004, 58:167-176.
39. Meyer-Franke A., Kaplan M.R., Pfrieger F.W., Barres B.A. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 1995, 15:805-819.
40. Morfini G., Pigino G., Mizuno N., Kikkawa M., Brady S.T. Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J. Neurosci. Res. 2007, 85:2620-2630.
41. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
42. Ning A., Cui J.Z., To E., Hsiao Ashe K., Matsubara J.A. Amyloid beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest. Ophthalmol. Vis. Sci. 2008, 49:5136-5143.
43. Nishimura I., Yang Y., Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004, 116:671-682.
44. Otvos L., Feiner L., Lang E., Szendrei G.I., Goedert M., Lee V.M. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J. Neurosci. Res. 1994, 39:669-673.
45. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. Semin. Ophthalmol. 2003, 18:50-57.
46. Perez M., Hernandez F., Gomez-Ramos A., Smith M., Perry G., Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 2002, 269:1484-1489.
47. Perez S.E., Lumayag S., Kovacs B., Mufson E.J., Xu S. beta-Amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest. Ophthalmol. Vis. Sci. 2008, 50:793-800.
48. Probst A., Götz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Bürki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 2000, 99:469-481.
49. Sadun A.A., Bassi C.J. Optic nerve damage in Alzheimer's disease. Ophthalmology 1990, 97:9-17.
50. Sato K., Higuchi M., Iwata N., Saido T.C., Sasamoto K. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 2004, 39:573-578.
51. Schlamp C.L., Li Y., Dietz J.A., Janssen K.T., Nickells R.W. Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci. 2006, 7:66.
52. Schmid S., Guenther E., Kohler K. Changes in Thy-1 antigen immunoreactivity in the rat retina during pre- and postnatal development. Neurosci. Lett. 1995, 199:91-94.
53. Shen S., Wiemelt A.P., McMorris F.A., Barres B.A. Retinal ganglion cells lose trophic responsiveness after axotomy. Neuron 1999, 23:285-295.
54. Spittaels K., Van den H.C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 1999, 155:2153-2165.
55. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
56. Sun A., Nguyen X.V., Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 2002, 50:463-472.
57. Tseng H., Kasmala L., Proia A., McKinnon S. Expression of protein markers of Alzheimer's disease in human glaucoma eyes. Invest. Ophthalmol. Vis. Sci. 2007, 48:3269.
58. Velasco A., Fraser G., Delobel P., Ghetti B., Lavenir I., Goedert M. Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2, 5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]. FEBS Lett. 2008, 582:901-906.
59. Vogelsberg-Ragaglia V., Bruce J., Richter-Landsberg C., Zhang B., Hong M., Trojanowski J.Q., Lee V.M. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol. Biol. Cell 2000, 11:4093-4104.
60. Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., Mandelkow E.M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10252-10257.
61. Yoneda S., Hara H., Hirata A., Fukushima M., Inomata Y., Tanihara H. Vitreous fluid levels of beta-amyloid(1-42) and tau in patients with retinal diseases. Jpn. J. Ophthalmol. 2005, 49:106-108.
62. Yoshida H., Goedert M. Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope. J. Neurochem. 2006, 99:154-164.
63. Yuan A., Kumar A., Peterhoff C., Duff K., Nixon R.A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 2008, 28:1682-1687.